Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardinal Health (NY: CAH )

99.02 +0.11 (+0.11%)
Streaming Delayed Price Updated: 12:43 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cardinal Health

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Battleground Stocks: 3 Heavily Shorted Meme Stocks to Watch
Heavily shorted meme stocks are often considered high-risk investments due to their volatility and potential for rapid gains or losses. 
Via InvestorPlace
Palantir Q4 Earnings Preview: Will The Data Software Company Deliver On CEO Expectations For A 'Strong Finish To The Year'?
Palantir Technologies Inc (NYSE: PLTR) is set to report fourth-quarter earnings results after the bell. The stock is up approximately 18% since the start of the year, but it's still down more than 40%... 
Via Benzinga
Why Palantir, Twilio, and HubSpot Each Surged Over 20% in January
Beaten-down enterprise software stocks got a relief rally in January. But will the good times last? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Cardinal Health's Earnings Outlook
Via Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
7 Analysts Have This to Say About Cardinal Health
Via Benzinga
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products 
Via News Direct
Topics Economy
Exposures Supply Chain
The Latest Analyst Ratings for Cardinal Health
Via Benzinga
6 Analysts Have This to Say About Cardinal Health
Via Benzinga
Analyst Ratings for Cardinal Health
Cardinal Health (NYSE:CAH) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the... 
Via Benzinga
Recap: Cardinal Health Q1 Earnings
Cardinal Health (NYSE:CAH) reported its Q1 earnings results on Friday, November 4, 2022 at 06:55 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
If the tide runs out, you won't be caught swimming naked with these two stocks in your portfolio. 
Via The Motley Fool
2 Dividend Aristocrat Stocks To Buy And Never Sell
A dividend aristocrat is a stock that is a member of the S&P500 that has raised dividend payments for at least 25 consecutive years. This filter alone is an effective way to identify companies with... 
Via Talk Markets
5 Stocks In S&P 500 ETF With 40% Gains In 2022
Despite the decline, some of the stocks in SPY’s portfolio have risen more than 40%. 
Via Talk Markets
The 8 Dividend Aristocrats With The Smallest Dividend Increases
Dividend Aristocrats comprise an elite group of 65 S&P 500 stocks with 25+ years of consecutive dividend increases. These stocks are celebrated amongst dividend growth investors and are considered... 
Via Talk Markets
Buy This Warren Buffett-Owned Stock for 2023 and Beyond
This healthcare products distributor's business model can withstand a recession. 
Via The Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
These companies are safe havens during tough times, with above-average dividends. 
Via The Motley Fool
Got $5,000? These 2 Dividend Stocks Are Yielding More Than 2%
These companies likely aren't done raising their dividend payments anytime soon. 
Via The Motley Fool
20 Dividend Growth Stocks For Faster Growth And Profit
The equal weight growth model was willing to accept faster-growing companies with lower current dividend yields, but faster-growing dividends. 
Via Talk Markets
Finding 20 Dividend Growth Stocks In A Bad Market
Starting in 2012, it became more and more difficult for prudent dividend growth stock investors looking for income. The stock market was trading at excessive valuations, and interest rates were at... 
Via Talk Markets
Dividend Income Update October 2022
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
US Authority Plans Massive Expansion Of Medication Access To Combat Opioid Overdose Crisis
Struggling with the opioid crisis, U.S. authorities plan to substantially expand access to medications tackling opioid addiction, such as methadone, buprenorphine, and naltrexone. 
Via Benzinga
Cardinal Health's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Cardinal Health (NYSE:CAH) showed a loss in earnings since Q4, totaling $111.00 million. Sales, on the other hand, increased by 5.31% to $49.60 billion during Q1. 
Via Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.